Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues
Portfolio Pulse from
Atara Biotherapeutics received a Complete Response Letter (CRL) from the FDA for its product EBVALLO, which is already approved in Europe. The CRL is due to minor issues and impacts Atara's cash flow due to delayed milestone payments and royalties. Atara has suspended its CAR-T pipeline to focus on EBVALLO.
January 21, 2025 | 5:30 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Atara Biotherapeutics received a CRL from the FDA for EBVALLO, affecting cash flow due to delayed milestone payments and royalties. The company is suspending its CAR-T pipeline to focus on EBVALLO.
The CRL from the FDA is a significant regulatory setback for Atara, impacting its cash flow due to delayed milestone payments and royalties. This has forced the company to suspend its CAR-T pipeline, indicating a strategic shift to focus on EBVALLO. The market may react negatively in the short term due to these financial and strategic implications.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100